Main Content

“2020health is an important and thoughtful contributor to the health debate”

Dr Sarah Wollaston MP, Chairman, Health Select Committee


PM Live Value-based pricing "not in patient interest"

The UK government's plans to introduce a new system of drug pricing that takes into account the wider value of a new medicine is neither in the patient interest nor national interest, according to a leading healthcare think-tank.

2020health said it approached the subject from the patient's perspective and concluded that the current PPRS system for drug reimbursement has kept UK medicine prices below the average in advanced countries and also supported R&D.


Read Full Article